Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Compared to the people who got a placebo, those who received Ozempic said they drank fewer drinks at home. They also drank ...

Alcohol is responsible for a significant portion of global disease and death, contributing to 2.6 million deaths annually. It ...